The results of a clinical trial into a new malaria vaccine candidate (RH5.1/Matrix-MTM) show it is well-tolerated and offers effective protection against the blood-stage of the disease—the first inoculation to do so.
First vaccine against blood-stage malaria is well-tolerated and offers effective protection in clinical trial
